Vasgene Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1998-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://vasgene.com
Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (100.0%)Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Phase 2
Recruiting
- Conditions
- Muscle-Invasive Bladder CarcinomaMetastatic Urothelial Carcinoma
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Vasgene Therapeutics, Inc
- Target Recruit Count
- 700
- Registration Number
- NCT06493552
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma
Phase 2
Recruiting
- Conditions
- Metastatic Urothelial Carcinoma
- Interventions
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Vasgene Therapeutics, Inc
- Target Recruit Count
- 38
- Registration Number
- NCT04486781
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
A Study of sEphB4-HSA in Kaposi Sarcoma
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Vasgene Therapeutics, Inc
- Target Recruit Count
- 65
- Registration Number
- NCT03993106
- Locations
- 🇺🇸
AIDS Healthcare Foundation, Beverly Hills, California, United States
🇺🇸CAN (Community AIDS Network) Community Health, Sarasota, Florida, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
News
No news found